Glioblastoma (GBM) is the most common and aggressive primary brain tumor. Any methods that may improve confirmation or early detection of progression are highly desirable. T2 relaxometry shows great promise in the monitoring of GBM patients following complex therapy. We found WB metrics, such as median 1/T2, correlated with PFS and were able to distinguish progression from pseudo-progression. A deep neural network trained on automatically segmented 1/T2 data achieved an F1 accuracy of 85% in classifying progression with a threshold of 18 months.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords